1. Trang chủ
  2. » Luận Văn - Báo Cáo

Tài liệu Báo cáo khoa học: Active and regulatory sites of cytosolic 5¢-nucleotidase doc

10 565 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Tiêu đề Active and regulatory sites of cytosolic 5'-nucleotidase
Tác giả Rossana Pesi, Simone Allegrini, Maria Giovanna Careddu, Daniela Nicole Filoni, Marcella Camici, Maria Grazia Tozzi
Trường học University of Pisa
Chuyên ngành Biochemistry
Thể loại Research article
Năm xuất bản 2010
Thành phố Pisa, Italy
Định dạng
Số trang 10
Dung lượng 365,26 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

There-fore, in addition to being involved in regulation of purine intracellular pool, the enzyme is also responsible Keywords cN-II active site; cN-II regulatory sites; cN-II structure;

Trang 1

Rossana Pesi1, Simone Allegrini2, Maria Giovanna Careddu1,2, Daniela Nicole Filoni1,

Marcella Camici1 and Maria Grazia Tozzi1

1 Dipartimento di Biologia, Unita` di Biochimica, Universita` di Pisa, Pisa, Italy

2 Dipartimento di Scienze del Farmaco, Universita` di Sassari, Sassari, Italy

Introduction

Cytosolic 5’-nucleotidase (cN-II) is a ubiquitous enzyme

that catalyses either the hydrolysis or the transfer of

phosphate esterified in the 5¢ position of

6-hydroxypu-rine monophosphate nucleosides [1] The transfer of

phosphate can lead to phosphorylation of inosine, guanosine and a number of their analogues [2] There-fore, in addition to being involved in regulation of purine intracellular pool, the enzyme is also responsible

Keywords

cN-II active site; cN-II regulatory sites;

cN-II structure; cytosolic 5¢-nucleotidase II

Correspondence

M G Tozzi, Dipartimento di Biologia,

Via S Zeno 51, Pisa, Italy

Fax: +39 502211450

Tel: +39 502211457

E-mail: mtozzi@biologia.unipi.it

(Received 19 July 2010, revised

10 September 2010, accepted

21 September 2010)

doi:10.1111/j.1742-4658.2010.07891.x

Cytosolic 5¢-nucleotidase (cN-II), which acts preferentially on 6-hydroxypu-rine nucleotides, is essential for the survival of several cell types cN-II catalyses both the hydrolysis of nucleotides and transfer of their phosphate moiety to a nucleoside acceptor through formation of a covalent phospho-intermediate Both activities are regulated by a number of phosphorylated compounds, such as diadenosine tetraphosphate (Ap4A), ADP, ATP, 2,3-bisphosphoglycerate (BPG) and phosphate On the basis of a partial crystal structure of cN-II, we mutated two residues located in the active site, Y55 and T56 We ascertained that the ability to catalyse the transfer

of phosphate depends on the presence of a bulky residue in the active site very close to the aspartate residue that forms the covalent phospho-intermediate The molecular model indicates two possible sites at which adenylic compounds may interact We mutated three residues that mediate interaction in the first activation site (R144, N154, I152) and three in the second (F127, M436 and H428), and found that Ap4A and ADP interact with the same site, but the sites for ATP and BPG remain uncertain The structural model indicates that cN-II is a homotetrameric protein that results from interaction through a specific interface B of two identical dimers that have arisen from interaction of two identical subunits through interface A Point mutations in the two interfaces and gel-filtration experi-ments indicated that the dimer is the smallest active oligomerization state Finally, gel-filtration and light-scattering experiments demonstrated that the native enzyme exists as a tetramer, and no further oligomerization is required for enzyme activation

Structured digital abstract

l MINT-8011572 : cN-II (uniprotkb: O46411 ) and cN-II (uniprotkb: O46411 ) bind ( MI:0407 ) by dynamic light scattering ( MI:0038 )

l MINT-8011493 , MINT-8011481 : cN-II (uniprotkb: O46411 ) and cN-II (uniprotkb: O46411 ) bind ( MI:0407 ) by molecular sieving ( MI:0071 )

Abbreviations

cN-II, cytosolic 5¢-nucleotidase; cN-III, cytosolic 5¢-nucleotidase III; cN-IA, cytosolic 5¢-nucleotidase IA; cN-IB, cytosolic 5¢-nucleotidase IB; cdN, cytosolic 5¢(3¢)-deoxyribonucleotidase; mdN, mitochondrial 5¢(3¢)-deoxyribonucleotidase.

Trang 2

for pro-drug activation and inactivation [3,4] It has

been demonstrated that the catalytic mechanism of

cN-II requires formation of a covalent

phospho-inter-mediate on an aspartate residue located in a conserved

motif (motif I) [5] This motif, together with three

other conserved motifs, is shared among the members

of the haloacid dehalogenase (HAD) superfamily,

including the soluble 5¢-nucleotidase family: cytosolic

5¢-nucleotidases cN-II, cN-III, cN-IA and cN-IB, and

both cytosolic and mitochondrial

5¢(3¢)-deoxyribonu-cleotidases [5] Even though all soluble 5¢-nu5¢(3¢)-deoxyribonu-cleotidases

share the same reaction mechanism and possess

con-served structural motifs in the catalytic site, only two

members of this family possess phosphotransferase

activity, namely cN-II and cN-III

cN-II has several unique aspects, such as its complex

regulation and the very high degree of primary

sequence conservation during evolution [5] These

aspects indicate that this enzyme plays an important

role cN-II knockdown through RNAi causes

apopto-sis in cultured cells [6] Furthermore, over-expression

of cN-II by more than 10-fold in HEK293 cells has

proved impossible to achieve, probably because of an

adverse effect on cell viability [7] The reaction rates

of both nucleotide hydrolysis and phosphate transfer

catalysed by cN-II appear to be regulated by a number

of phosphorylated compounds such as ADP, ATP,

BPG, Ap4A and polyphosphates These compounds

act as allosteric activators ATP causes an increase in

Vmax of approximately 10-fold, with little effect on Km

for the substrate IMP [8,9]

Free inorganic phosphate, on the other hand, acts as

an allosteric inhibitor, causing a 20-fold increase in Km

for the substrate IMP with little effect on Vmax

Inter-estingly, ATP partially counteracts the effect of

phos-phate, by increasing Vmax; however, it is unable to

reverse the increase in Km[9] cN-II has been described

as a homotetramer with the ability to change its

oligo-merization state in response to the presence of

activa-tors or inhibiactiva-tors It has been suggested that the

change in the oligomerization state is accompanied by

a change in specific activity [10] However, this simple

model does not explain the kinetic evidence described

above

Despite its cytosolic location, cN-II has particularly

poor solubility This is why it has been difficult to

obtain the crystal structure of the whole protein A

truncated form of cN-II lacking the last 25 amino

acids is significantly more soluble than the wild-type

enzyme, and was recently crystallized [11] The

crystal-lographic model, constructed by ordering 487 residues

(1-400 and 417-488) out of 561, indicates a

homotetra-meric protein resulting from interaction through a

specific interface (interface B) of two identical dimers that arise from interaction of two identical subunits through interface A Because of the presence of adeno-sine bound to the crystallized protein, Wallde´n et al [11] identified two putative effector sites, and suggested that effector site 1, close to interface A, might interact with BPG and Ap4A, while ATP and ADP might bind

to effector site 2

In a previous paper, two active forms of cN-II were identified in extracts from different organs [12] The two forms purified from calf thymus showed different behav-iour with activators The heavier form (form A) has a high-affinity regulatory site for BPG, while ADP and ATP share a different site The lighter form (form B) has three different sites for the three activators [5,12] Although many papers have been published in the last few years describing structural and functional fea-tures of cN-II, fundamental aspects of how the enzyme functions remain to be unravelled, in particular the number and location of the interaction sites for the activators and inhibitors, the relationship between activity and enzyme oligomerization state, and, finally, the amino acid residue(s) responsible for phospho-transferase ability of cN-II We have utilized a mecha-nistic approach in order to increase knowledge on these topics

Results Active site and phosphotransferase reaction Figure 1 shows the aligned sequences of motif I for the six intracellular 5¢-nucleotidases Of the six enzymes, only cN-II and cN-III possess a Thr instead of a Val (position 56 of cN-II, boxed in Fig 1) [11] These are the only two enzymes for which phosphotransferase activity has been unquestionably ascertained, and Wallde´n et al [11] suggested that the presence of T56

Fig 1 Aligned conserved motif I of the six known intracellular human 5¢-nucleotidases: cN-II, cN-III, cN-IA, cN-IB, cytosolic 5¢(3¢)-deoxyribonucleotidase (cdN) and mitochondrial 5¢(3¢)-deoxyribonu-cleotidase (mdN) Residues 55 and 56 of cN-II are indicated in bold.

Trang 3

might be important for this activity However, we

noted that there is another variable residue near T56

In position 55 of cN-II, a Tyr is present that is

substi-tuted by Met in cN-III and by Ala or Gly in the other

enzymes Therefore, the two phosphotransferases have

a bulkier amino acid in this position compared to the

other four enzymes, which have amino acids with very

small side chains We decided to construct two

mutants of motif I at positions 55 (Y55G) and 56

(T56V) in order to ascertain whether one of them is

responsible for the phosphotransferase activity

Deter-mination of kinetic parameters showed that

substitu-tion of Tyr55 by a smaller residue causes a dramatic

increase in the ratio of nucleotidase to

phosphotrans-ferase activity The affinity for the substrates inosine

and IMP remains unaltered, and the effect of the

enzyme activators ATP and Mg2+ is also unchanged

(Table 1) Furthermore, by simultaneously measuring

the rate of nucleoside and phosphate production from

IMP and monophosphate synthesis from inosine (see

Experimental procedures), we observed that, in the

wild-type, the transfer of phosphate to inosine

accounts for 53% of the phosphate produced from

IMP, but only for 11% with the mutated Y55G

enzyme under the same experimental conditions

(Fig 2) However, substituting Thr56 by Val produced

an enzyme with a lower turnover but the same

func-tional characteristics as the wild-type enzyme, included

the nucleotidase⁄ phosphotransferase ratio (Table 1)

Regulatory sites

Effector site 1 is located near subunit interface A, and

is believed to interact with the activator Ap4A, by

binding one adenosine moiety in each subunit (Fig 3)

We mutated Arg144, which has been proposed to bind

the phosphate moiety of nucleotide activators, Ile152,

which is thought to interact with the adenylic moiety

of the activator, and Asn154, which probably interacts

with the purine ring through a hydrogen bond [11],

substituting these amino acids by negatively charged

residues For putative effector site 2, we mutated

Phe127 and His428, as adenosine is presumably stacked between these two residues, and Met436, which forms a hydrogen bond with the purine ring through its carbonylic group [11] (Fig 3) We substi-tuted the first two residues by a negatively charged res-idue to discourage stacking, and replaced Met436 with

a bulkier amino acid (Trp)

Putative effector site 1 None of the mutations produced had a significant effect on Kmfor the two principal substrates (Table 2)

Table 1 Effect of point mutations on various kinetic parameters of recombinant bovine cN-II Nucleotidase and phosphotransferase activi-ties were measured as described in Experimental procedures Values are means ± SD of at least three independent assays k cat refers to nucleotidase activity and is measured at saturating concentrations of IMP and sub-saturating concentrations of inosine The K50for ATP was measured as phosphotransferase activity, while for Mg 2+ , it was measured as nucleotidase activity.

cN-II

Nucleotidase ⁄

phosphotransferase

Km(inosine) (m M )

Km(IMP) (m M ) k cat (s)1)

K50(Mg 2+ ) (m M )

K50(ATP) (m M )

50

100

0

Ino H2O

E + IMP

E + IMP E-P E + Pi

Ino

Fig 2 Rate of inosine, IMP and P i production catalysed by wild-type cN-II (black bars) or mutant Y55G (white bars) in the presence

of 2 m M IMP and 1.4 m M inosine (Ino) as substrates The assays were performed as described in Experimental procedures For wild-type and Y55G, 100% activity corresponds to 32 and 18 UÆmL)1, respectively The upper scheme indicates the catalytic mechanism

of cN-II E, enzyme; P, phosphate The products measured are boxed.

Trang 4

Mutant R144E showed an altered affinity for all the activators tested, N154D was normally activated by ATP and BPG but activation by ADP and Ap4A was completely prevented, as is the case for I152D, which showed a higher K50for ATP and BPG

Putative effector site 2 Study of cN-II crystallized in the presence of adeno-sine indicates that this nucleoside binds to this site, even though only the amino acid residues involved in the binding of the purine base were identified, while the ribose moiety was completely disordered [11] Mutation of two residues involved in the binding of adenine (F127E and M436W) had no effect on the functional characteristics of the enzyme, except for an increase in the K50for Ap4A for mutant M436W The mutations did not alter the activatory capacity of all the compounds tested The mutant H428D was almost insensitive to all known activators of cN-II (Table 2)

CN-II subunit oligomerization Using ‘FirstGlance in Jmol’ (http://molvis.sdsc.edu/ fgij/), we analysed the cN-II crystal structure described

by Wallde´n et al [11] We mutated three amino acids

at interface A (Phe36, Tyr115 and Asp396) and two at interface B (Lys311 and Gly319)

Interface A

In the model proposed on the basis of the crystal struc-ture, interface A is involved in formation of a dimeric structure (Fig 3) Fifty-three amino acids contribute to interaction of the two monomers by forming both hydrogen bonds and salt bridges Some of these residues are near to effector site 1 We designed our mutants in

Fig 3 Model of the homotetrameric quaternary structure of cN-II

showing interfaces A and B and the Mg 2+ site The inset shows

the tertiary structure of each subunit Effector sites 1 and 2 and

the active site are shown.

Table 2 Effect of point mutations on various kinetic parameters of recombinant bovine cN-II Nucleotidase and phosphotransferase activi-ties were measured as described in Experimental procedures Values are means ± SD of at least three independent assays K50values for

P i , ATP, ADP and Ap 4 A were measured as phosphotransferase activity, while those for BPG and Mg2+were measured as nucleotidase activ-ity The extent of activation, when present, was between 5- and 10-fold (1) Mutation in putative effector site 1; (2) mutation in putative effector site 2 NA, no activation.

cN-II

Km(IMP)

(m M )

Km(inosine) (m M )

K50(Mg 2+ ) (m M )

K50(Pi) (m M )

K50(BPG) (m M )

K50(ATP) (m M )

K50(ADP) (m M )

K50(Ap4A) (m M )

R144E (1) 0.10 ± 0.05 1.0 ± 0.2 2.0 ± 1.0 6.5 ± 1.0 5.0 ± 1.50 30.0 ± 5.0 33.0 ± 6.0 1.6 ± 1.00

Trang 5

an attempt to interfere with monomer aggregation via

interface A by introducing or deleting charged residues

or altering molecular hindrance One of the mutated

amino acids (Tyr115) is located very close to Arg144,

which is part of effector site 1 (Fig S1) The mutant

F36R was inactive, while Y115A behaved normally and

D396A was only activated by BPG (Table 3)

Interface B

The structure described by Wallde´n et al [11] indicates

that the active tetramer is formed by interaction between

two identical dimers via interface B: this interface

con-tains 28 aminoacid residues, of which 8 make hydrogen

bonds (Fig 3) We constructed two mutants by

introdu-cing a negative charged residue or substituting a residue

with a non polar group (K311A), thus forming both

hydrogen and van der Waals interactions The two

mutants showed kinetic characteristics similar to those

of the wild-type (Table 3) FPLC gel-filtration

chroma-tography of purified recombinant wild-type cN-II

indi-cated that this enzyme exists in solution as a tetramer

(molecular mass 260 kDa) (Fig 4) Actually, the

chro-matogram showed two peaks, but the first was inactive

Immunoblotting of both peaks indicated cross-reactivity

with specific antibodies against cN-II, but the first

inac-tive peak disappeared when Escherichia coli cells

expressing cN-II were grown at 20C instead of 37 C

(data not shown) A dimeric active form (130 kDa) was

present in addition to the tetramer for mutants K311A

and G319D (mutations at interface B) (Fig 4)

Finally, we investigated the chromatographic

behav-iour of recombinant wild-type enzyme in the presence of

ATP and Mg2+as an activator and Pias an inhibitor

Figure 5 shows that the enzyme exists and functions as a

tetramer irrespectively of the presence of activator or

inhibitor We also performed light-scattering

measure-ments of the enzyme alone or in the presence of its

effec-tors There was no change in molecular mass in the

presence of enzyme activators or inhibitors (Table 4)

Discussion Active site The soluble 5¢-nucleotidase family shares four con-served motifs with the HAD superfamily that are involved in the reaction mechanism [5] Resolution of the crystal structure of some family members indicated that the active site contains all the conserved motifs, whose role in catalysis was determined through a mechanistic approach [5,11,13] Other than these con-served motifs, cN-IA, cN-IB, cN-II, cN-III and the cytosolic and mitochondrial 5¢(3¢)-deoxyribonucleotid-ases differ considerably in their primary structure Despite this poor similarity, there is much evidence to indicate that all members of soluble 5¢-nucleotidase family share the same reaction mechanism, proceeding through a covalent phospho-enzyme intermediate [13,14] Phospho-cN-II has been isolated, and the phosphate has been found to be localized to a con-served aspartate residue (D52) in the first of the four conserved motifs [13] Formation of a phospho-inter-mediate suggests the possibility that the enzyme cataly-ses transfer of phosphate to a suitable acceptor [15]

A number of HAD superfamily members are able to catalyse a phosphotransferase reaction, including at least two soluble nucleotidases (cN-II and cN-III) The aligned sequence of motif I of soluble nucleotidases indicates that both nucleotidases with phosphotransfer-ase activity had a Thr instead of Val in the fifth posi-tion after the phosphorylated Asp, and a relatively bulky residue in the fourth position instead of Gly, which is present in all the other nucleotidases On this basis, we mutated two residues in motif I, Thr56 and Tyr55 Thr56 was substituted by Val, and Tyr55 was substituted by Gly Our results indicate that the pres-ence of Thr or Val in position 56 is not relevant for the nucleotidase⁄ phosphotransferase ratio However, the increase in flexibility very close to Asp54, which

Table 3 Effect of point mutations on various kinetic parameters of recombinant bovine cN-II Nucleotidase and phosphotransferase activi-ties were measured as described in Experimental procedures K 50 values for P i , ATP, ADP and Ap 4 A were measured as phosphotransferase activity, while those for BPG and Mg 2+ were measured as nucleotidase activity The extent of activation, when present, was between 5- and 10-fold Values are means ± SD of at least three independent assays (A) Mutation in interface A; (B) mutation in interface B NM, not measurable NA, no activation.

cN-II

K m (IMP)

(m M )

K m (inosine) (m M )

K 50 (Mg2+) (m M )

K 50 (P i ) (m M )

K 50 (BPG) (m M )

K 50 (ATP) (m M )

K 50 (ADP) (m M )

K 50 (Ap 4 A) (m M ) Wild-type 0.10 ± 0.02 1.0 ± 0.2 2.0 ± 0.5 2.0 ± 0.3 0.3 ± 0.06 1.0 ± 0.3 2.2 ± 0.5 0.10 ± 0.05

K311A (B) 0.04 ± 0.03 0.2 ± 0.5 0.7 ± 0.5 2.0 ± 0.4 0.5 ± 0.04 7.3 ± 1.5 1.00 ± 0.6 0.25 ± 0.07 G319D (B) 0.05 ± 0.04 0.5 ± 0.5 2.5 ± 0.6 1.6 ± 0.7 0.5 ± 0.03 3.0 ± 1.0 2.00 ± 0.5 0.25 ± 0.05

Trang 6

participates in binding of the phosphate [13], obtained

with the Y55G mutant, causes an increase in turnover

for the nucleotidase reaction, and, as a consequence, a

large increase in the nucleotidase⁄ phosphotransferase

ratio

Regulatory sites

cN-II is activated by BPG, a number of triphosphate

and diphosphate nucleosides (ATP and ADP being the

best activators), Ap4A and polyphosphates

Con-versely, orthophosphate has an inhibitory effect

Kinetic studies have indicated that ATP (and presum-ably other phosphorylated compounds) causes stabil-ization of an enzyme form with a high kcat, without substantial alteration of the Km for the substrates, while orthophosphate stabilizes a form at high Kmwith

no effect on kcat If ATP and phosphate are present at the same time, an enzyme form with high Kmand high

kcatis observed [9] Therefore, depending on the effec-tor, cN-II may be present as one of two structures

.

Retention time (min)

A

B

C

.

.

Fig 5 FPLC profiles of wild-type cN-II alone (A), or in the presence

of 5 m M ATP and 10 m M MgCl2(B), or in the presence of 5 m M Pi and 10 m M MgCl 2 (C) The column, prepared and eluted as described in Experimental procedures, was loaded with approxi-mately 150 lg of purified protein, and the activity was measured as the rate of IMP production in the presence of inosine (phospho-transferase activity) as described in Experimental procedures Arrows indicate the molecular mass of the marker proteins thyro-globulin (670 kDa), apoferritin (443 kDa), b-amylase (210 kDa) and alcohol dehydrogenase (150 kDa).

.

Retention time (min)

WT

G319D

K311A

.

Fig 4 FPLC profiles of wild-type cN-II, and two mutants in

inter-face B: G319D and K311A The column, prepared and eluted as

described in Experimental procedures, was loaded with

approxi-mately 150 lg of purified protein, and the activity was measured as

the rate of phosphate production in the presence of IMP

(phospha-tase) as described in Experimental procedures Arrows indicate the

molecular mass of the marker proteins thyroglobulin (670 kDa),

apoferritin (443 kDa), b-amylase (210 kDa) and alcohol

dehydroge-nase (150 kDa).

Trang 7

with high and low Km In addition, a low and high kcat

may be associated with each structure It has also been

suggested, on the basis of kinetic characterization, that

the enzyme has at least three effector sites, one for

ATP, one for ADP and one for BPG [5,12] On the

basis of the results obtained from crystallization of a

truncated form of cN-II [11], we constructed point

mutants for a number of amino acid residues located

in putative effector sites 1 and 2 and involved in

bind-ing of adenylic nucleotides and BPG

Our results partially confirm the molecular

model-ling, suggesting that effector site 1 is the binding site

for Ap4A and that ADP binds this site as well Ap4A

binds between two subunits with one adenosine moiety

in each subunit [11], but ADP may possibly fill the

whole site in each subunit and attain the same result

Mutant N154D shows a decrease in the value of K50

for Mg2+ Moreover, the mutated enzyme showed

some activity even in the absence of added Mg2+,

whereas all the other active mutants, as well as the

wild-type enzyme, are completely dependent on

addi-tion of the metal This behaviour may be due to the

proximity of Asn154 to the active site (Fig S2), and, in

particular, a modification in the interaction of this

resi-due with Asp351 (directly involved in Mg2+ binding)

and His352 both belonging to motif III Remarkably,

mutant D396A, in which the mutation is located in

interface A, very close to effector site 1 and the active

site, shows a similar increase in affinity for Mg2+ Our

results also indicate that ATP and BPG probably bind

to a different site and that this is effector site 2 Point

mutations at this site result in either generalized

impair-ment of enzyme regulation or characteristics very

simi-lar to those of the wild-type As virtually all purine and

pyrimidine triphosphates have some activatory effect

on cN-II, the interaction site is likely to be more

selec-tive for the phosphorylated sugar moiety than for the

base Therefore, binding of adenosine to effector site 2,

as demonstrated by the cN-II crystal structure [11], may not be indicative of the location of the nucleoside triphosphate effector site

CN-II subunit oligomerization CN-II has been purified from various sources and has always been described as a homotetramer [16,17] The crystal structure suggests that the tetramer arises from interaction of two dimers through interface B Muta-tions in interface A, through which two monomers interact, and which is very close to the effector site 1, either resulted in a completely inactive enzyme or strongly interfered with activation by ADP and Ap4A This indirectly confirms that effector site 1 is specific for these compounds Mutation of amino acid residues located in interface B generated proteins for which an active dimeric form was detected in addition to the tet-ramer However, stabilization of the dimeric form had

no effect on the catalytic capacity of the enzyme Our results show that the monomer is probably inactive, and the dimer is the smallest active cN-II quaternary structure FPLC analysis of purified recombinant enzymes shows a heavier protein (720 kDa) in addition

to the proteins at the expected molecular mass This protein was an unusual oligomerization state of a pro-tein that was identified by immunoblotting as cN-II but completely inactive E coli produces a small amount of cN-II that is correctly folded and a large amount of incorrectly folded and insoluble protein It

is conceivable that a cN-II protein that is incorrectly folded but still soluble is also produced A decrease in growth temperature resulted in disappearance of the heavier inactive peak Furthermore, FPLC analysis of the recombinant wild-type cN-II showed the presence

of the tetrameric active form irrespective of the pres-ence of effectors This result disagrees with other results obtained on recombinant human cN-II [10], which is almost identical to our bovine enzyme To support our finding, we used light scattering, a tech-nique that, unlike gel-filtration chromatography, does not require protein dilution However, light-scattering experiments confirmed that enzyme activation or inhi-bition is not followed by a change in enzyme subunit oligomerization

In conclusion, our results confirm that there is indeed

an activatory site specific for Ap4A located at the inter-face between two subunits (interinter-face A) This site may also accommodate ADP at lower affinity, but resulting

in the same level of activation as Ap4A ATP binds to

a different site; however, it was not possible to confirm this as effector site 2 indicated by the crystal structure obtained in the presence of adenosine In contrast to

Table 4 Variation of the protein molecular mass in the presence

of specific effectors as estimated by the ratio of the scattered light

intensity Values are means ± SD of at least three measurements.

cN-II in 20 m M Tris ⁄ HCl, pH 8, +0.2 M NaCl (control)

(control), +5 m M ⁄ 10 m M ATP ⁄ Mg 2+ 1.16 ± 0.06

(control), +10 m M ⁄ 10 m M ATP ⁄ Mg 2+

1.15 ± 0.08

(control), +5 m M ⁄ 10 m M P i ⁄ Mg 2+ 0.95 ± 0.07

a

Ratio of molecular mass in the presence of specific effectors to

that of the free protein.

Trang 8

the suggestion by Wallde´n [11], we demonstrated that

BPG does not bind effector site 1 Finally, mutations

at the interfaces and gel-filtration experiments indicated

that the tetramer is the major quaternary structure of

cN-II, irrespectively of the presence of effectors, but

that the dimer may also be stable and active

Experimental procedures

Materials

DpnI was provided by New England Biolabs (Ipswich, MA,

USA) and Pfu DNA polymerase by Promega (Madison,

WI, USA) Ni-NTA agars was purchased from Qiagen

(Valencia, CA, USA) [8-14C]-inosine and [8-14C]-IMP were

obtained from Sigma-Aldrich (St Louis, MO, USA)

Opti-phase ‘HiSafe’ 3 scintillation liquid was obtained from

Per-kin-Elmer (Waltham, MA, USA) Superdex-200 was

purchased from GE Healthcare (Piscataway, NJ, USA) All

other chemicals were of reagent grade

Site-directed mutagenesis

The point mutants F36R, Y115A, F127E, I152D, R144E,

N154D, K311A, G319D, D396A and M436W were

obtained using the PCR-based site-directed mutagenesis

method described by Fisher and Pei [18], and the point

mutants Y55G, T56V and H428D were produced as

described in the QuikChangesite-directed mutagenesis kit

manual (Stratagene, La Jolla, CA, USA) The primers used

are listed inTable 5

Expression and purification of the recombinant

proteins

Expression of the recombinant mutants was performed as

previously described [19] The 6· His-tagged proteins were

purified using the Ni-NTA agar method as described in the QIAexpressionist handbook (Qiagen) The protein con-centration was determined using the Bradford method [20], with BSA as the standard

Enzyme assays

The nucleotidase activity of cN-II and its mutants was mea-sured as the rate of [8-14C]-inosine formation from 2 mm [8-14C]-IMP in the presence of 1.4 mm inosine, 20 mm MgCl2, 4.5 mm ATP and 5 mm dithiothreitol, as previously described [9] Phosphotransferase activity was measured as the rate of [8-14C]-IMP formation from 1.4 mm [8-14 C]-ino-sine, in the presence of 2 mm IMP, 20 mm MgCl2, 4.5 mm ATP and 5 mm dithiothreitol, as previously described [9] For determination of kinetic parameters (Km and kcat), the concentration of the labelled substrates ranged from 0.02 to

4 mm A plot of the dependence of the rate of phospho-transferase activity on MgCl2, ATP, ADP and BPG con-centration was used to determine the value of K50for these compounds Under these experimental conditions, the accu-mulation of radiolabelled inosine (nucleotidase activity) rep-resents the sum of the phosphatase and the phosphotransferase activities It has been previously reported that, at a concentration close to the Km value (1.4 mm), inosine reduces phosphatase activity to 50% without affecting the Vmaxfor both reactions [9] Thus, the expected value of 2 was determined for the ratio between nucleotidase and phosphotransferase activities under the experimental conditions used for the wild-type recombinant cN-II assay Accordingly, an alteration of this ratio for a mutant was considered as caused either by an alteration of the Kmvalue for one of the two substrates or by a variation

of the kcat value for one of the two activities When required, the rate of phosphate formation (phosphatase activity) was measured as described by Chifflet et al [21] One unit of enzyme activity is the amount of enzyme

Table 5 Primers used for site-directed mutagenesis.

Trang 9

required to convert 1 lmol of substrate to product per

min-ute under the assay conditions

Gel-filtration chromatography

The gel-filtration chromatography was performed on a

FPLC system utilizing a Superdex-200 column

(1.2· 32 cm) Purified wild-type or mutant cN-II (150 lg)

was loaded onto the column, and the chromatography was

performed at a flow rate of 0.3 mLÆmin)1 using 50 mm

Tris⁄ HCl, pH 7.4, with addition of 200 mm NaCl

Frac-tions of 0.1 mL were collected

Light scattering

The intensity of light scattered at 90 from the incident

beam was measured using a spectrofluorometer

(Fluoro-max-4; Horiba, Edison, NJ, USA) The wavelength of the

incident light was 350 nm, and the band-pass used in the

excitation and emission monochromators was 1.0 nm The

sample cell (fluorescence cell 1· 1 cm2 cross-section) was

cleaned using water filtered through 0.22 lm pore

mem-brane Protein and additive solution were passed through

identical filters All reagents were dissolved in 20 mm

Tris⁄ HCl + 0.2 m NaCl, pH 8, and the enzyme

concentra-tion ranged between 0.09 and 0.14 mgÆmL)1 Scattering

intensities were compared between samples that had the

same protein concentration and refractive index Under

these conditions, their ratio, according to Parr and

Ham-mes [22], is proportional to the ratio of molecular mass

Acknowledgements

We would like to thank Dr Giovanni Strambini and

Dr Margherita Gonelli of the Institute of Biophysics

(National Research Centre, Pisa, Italy) for the

light-scattering analysis We would also like to thank Dr

Adrian Wallwork for careful language revision of the

manuscript This work was supported by a grant from

the Ministero dell’Istruzione, dell’Universita` e della

Ricerca and by local funds from the University of

Pisa

References

1 Tozzi MG, Camici M, Pesi R, Allegrini S, Sgarrella F

& Ipata PL (1991) Nucleoside phosphotransferase

activ-ity of human colon carcinoma cytosolic 5¢-nucleotidase

Arch Biochem Biophys 291, 212–217

2 Banditelli S, Baiocchi C, Pesi R, Allegrini S, Turriani

M, Ipata PL, Camici M & Tozzi MG (1996) The

phosphotransferase activity of cytosolic 5¢-nucleotidase;

a purine analog phosphorylating enzyme Int J Biochem

Cell Biol 2, 711–720

3 Hunsucker SA, Mitchell BS & Spychala J (2005) The 5¢-nucleotidases as regulators of nucleotide and drug metabolism Pharmacol Ther 107, 1–30

4 Galmarini CM, Jordheim L & Dumontet C (2003) Role

of IMP-selective 5¢-nucleotidase (cN-II) in haematologi-cal malignancies Leuk Lymphoma 44, 1105–1111

5 Allegrini S, Scaloni A, Careddu MG, Cuccu G, D’Am-brosio C, Pesi R, Camici M, Ferrara L & Tozzi MG (2004) Mechanistic studies on bovine cytosolic 5¢-nucle-otidase II, an enzyme belonging to the HAD superfam-ily Eur J Biochem 271, 4881–4891

6 Careddu MG, Allegrini S, Pesi R, Camici M, Garcia-Gil M & Tozzi MG (2008) Knockdown of cytosolic 5¢-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells Biochim Biophys Acta 1783, 1529–1535

7 Rampazzo C, Gazziola C, Ferraro P, Gallinaro L, Johansson M, Reichard P & Bianchi V (1999) Human high-Km5¢-nucleotidase: effects of overexpression of the cloned cDNA in cultured human cells Eur J Biochem 261, 689–697

8 Spychala J, Madrid-Marina V & Fox IH (1988) High

Kmsoluble 5¢-nucleotidase from human placenta Prop-erties and allosteric regulation by IMP and ATP J Biol Chem 263, 18759–18765

9 Pesi R, Turriani M, Allegrini S, Scolozzi C, Camici M, Ipata PL & Tozzi MG (1994) The bifunctional cytosolic 5¢-nucleotidase: regulation of the phosphotransferase and nucleotidase activities Arch Biochem Biophys 312, 75–80

10 Spychala J, Chen V, Oka J & Mitchell BS (1999) ATP and phosphate reciprocally affect subunit association of human recombinant high Km 5¢-nucleotidase Role for the C-terminal polyglutamic acid tract in subunit associ-ation and catalytic activity Eur J Biochem 259, 851– 858

11 Wallden K, Stenmark P, Nyman T, Flodin S, Graslund

S, Loppnau P, Bianchi V & Nordlund P (2007) Crystal structure of human cytosolic 5¢-nucleotidase II: insights into allosteric regulation and substrate recognition

J Biol Chem 282, 17828–17836

12 Pesi R, Baiocchi C, Allegrini S, Moretti E, Sgarrella F, Camici M & Tozzi MG (1998) Identification, separation and characterisation of two forms of cytosolic 5¢-nucle-otidase⁄ nucleoside phosphotransferase in calf thymus Biol Chem 379, 699–704

13 Allegrini S, Scaloni A, Ferrara L, Pesi R, Pinna P, Sgarrella F, Camici M, Eriksson S & Tozzi MG (2001) Bovine cytosolic 5¢-nucleotidase acts through the forma-tion of an aspartate 52-phosphoenzyme intermediate

J Biol Chem 276, 33526–33532

14 Baiocchi C, Pesi R, Camici M, Itoh R & Tozzi MG (1996) Mechanism of the reaction catalysed by cytosolic 5¢-nucleotidase ⁄ phosphotransferase: formation of a phosphorylated intermediate Biochem J 317, 797–801

Trang 10

15 Fersht A (1999) Structure and Mechanism in Protein

Science – A Guide to Enzyme Catalysis and Protein

Folding, 2nd edn W.H Freeman and Company, New

York, NY

16 Zimmermann H (1992) 5¢-nucleotidase: molecular

struc-ture and functional aspects Biochem J 285, 345–365

17 Itoh R (1993) IMP–GMP 5¢-nucleotidase Comp

Biochem Physiol B 105, 13–19

18 Fisher CL & Pei GK (1997) Modification of a

PCR-based site-directed mutagenesis method BioTechniques

23, 570–571

19 Allegrini S, Pesi R, Tozzi MG, Fiol CJ, Johnson RB &

Eriksson S (1997) Bovine cytosolic IMP⁄ GMP-specific

5¢-nucleotidase: cloning and expression of active enzyme

in Escherichia coli Biochem J 328, 483–487

20 Bradford MM (1976) A rapid and sensitive method for

the quantitation of microgram quantities of protein

uti-lizing the principle of protein–dye binding Anal

Bio-chem 72, 248–254

21 Chifflet S, Torriglia A, Chiesa R & Tolosa S (1988)

A method for the determination of inorganic phosphate

in the presence of labile organic phosphate and high

concentrations of protein: application to lens ATPases

Anal Biochem 168, 1–4

22 Parr GR & Hammes GG (1975) Subunit dissociation and unfolding of rabbit muscle phosphofructokinase by guanidine by hydrochloride Biochemistry 14, 1600– 1605

Supporting information The following supplementary material is available: Fig S1 Proximity between effector site 1 and inter-face A

Fig S2 Proximity between effector site 1 and the active site

This supplementary material can be found in the online version of this article

Please note: As a service to our authors and readers, this journal provides supporting information supplied

by the authors Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset Technical support issues arising from supporting information (other than missing files) should be addressed to the authors

Ngày đăng: 15/02/2014, 01:20

TỪ KHÓA LIÊN QUAN

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm